You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Toward the Development of a Protein: Non-protein Macromolecular Adjuvants

    SBC: Hafion LLC            Topic: NIAID

    An existing problem being faced in the development of new vaccines is the need for targeting bacterial infections that occur at mucosal sites such as the upper airway and the gastrointestinal tractOvercoming this problem will require the use of novel vaccine formulations andin particularthe use of novel immune enhancing agentsadjuvantsthat promote immune responses that are effective at mucosal sit ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Enzyme Replacement Therapy for Complement C2-Deficiency

    SBC: Nectagen, Inc.            Topic: NIAID

    The goal of this Phase I SBIR project is to develop a scalable method of Cpurification for use in Creplacement therapy based on a novel immunoaffinity chromatography resinDeficiency of complement CC Dis reported to be the most common hereditary defect among complement components with a prevalence ofPatients with homozygous complete deficiency suffer from recurring pyrogenic infections with encapsu ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Diagnostic Test for Detecting Recent Seizures in Epilepsy Patients

    SBC: Sceptor Industries, Inc.            Topic: 106

    Project SummaryAbstractEpilepsy affects approximatelyof the world populationtotaling andgtmillion patientsWhile anti epileptic drugAEDtreatment is successful in many patientsof patients continue to experience seizures causing physicians to adjust change medications or other treatment parametersCurrent diagnostic tools are incapable of differentiating between patients experiencing a recent seizure ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Exo-Seq for the single molecule of DNA molecules

    SBC: Digital Nanogenetics LLC            Topic: 172

    ABSTRACT The long term goal of this project is the commercial development of a low cost Single Molecule SequencingSMStechnologycalled Exo Seqwhich employs a sequencing by subtraction strategy for high fidelity disassembly of low amounts of unamplified DNAsIn spite of the SMS approachExo Seq possesses superior single pass base call accuracyandgtusing a multiparameter identification strategy that ta ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Ultrasound-facilitated endovascular laser thrombolysis

    SBC: Vesarex LLC            Topic: NHLBI

    AbstractThrombosis affectstopatients in the United States annuallyand results in more thandeaths each yearRapid and complete removal of blood clots to re canalize blood vessels is criticalThe goal of this study is to develop a high efficient endovascular method to remove blood clots by combining laser and ultrasound techniquesCavitation is the main mechanism for both laser and ultrasound thromboly ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Assessment of Peripherally Circulating Plasma Proteins and Clinical Risks to Differentiate Epileptic Seizure from Psychogenic Nonepileptic Seizure

    SBC: Sceptor Industries, Inc.            Topic: 106

    Project SummaryAbstract Accurately diagnosing epilepsy is very challenging and time consuming because clinicians rarely observe the actual seizureand there are many different types of seizures and epilepsy syndromes with differing presentationsFurthermoreother neurological disorders can be mimics of seizures leading to erroneous diagnosisinappropriate treatments with significant potential adverse ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. The Rapid-Production of the High-Performance and Affordable Cadmium Telluride and Cadmium Zinc Telluride for Medical Imaging Applications

    SBC: Radiation Detection Technologies, Inc.            Topic: NIBIB

    The high spatial resolution and energy resolution of cadmium zinc tellurideCZTand cadmium tellurideCdTecompared to that of scintillatorsoffers superior image quality in Nuclear medicine and X rayimaging applicationsi eSPECTPETCTBone DensitometryOncologyDental imagingAirportsecurityetcEven after two decades of researchCZT and CdTe remain the desired choice for roomtemperature radiation detectionbut ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Commercialization of Enzyme Modified Carbon-Fiber Electrodes Paired with Voltammetry for Simultaneous Real-Time Monitoring of Electroactive and Non-Electroactive Species at Discrete Brain Locations

    SBC: Pinnacle Technology, Inc.            Topic: 101

    ABSTRACT Commercially available biosensors are designed to measure only one molecule at a time at a given recording siteThis is a problem because chemical signals in the brain do not work in isolationratherneurotransmission involves many chemical species simultaneously released and little is known about how specific neurochemicals fluctuate relative to one anotherUnderstanding these relationships ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. NEW DERIVATIZATION REAGENTS AND METHODS FOR PEPTIDE ANALYSIS

    SBC: Oread Laboratories Inc            Topic: N/A

    THE OBJECTIVE OF THIS PROPOSAL IS COMMERCIAL EVALUATION OF NEW ANALYTICAL REAGENTS AND METHODS DISCOVERED AND BEING DISCOVERED BY THE CENTER FOR BIOANALYTICAL RESEARCH AT THE UNIVERSITY OF KANSAS. THE SPECIFIC TECHNOLOGY WHICH WILL BE EXAMINED IS CONCERNED WITH NEW ANALYTICAL METHODS WHICH WOULD ALLOW SEVERAL-FOLD GREATER SENSITIVITY IN MEASUREMENT OF AMINO ACIDS AND PEPTIDES IN BIOLOGICAL MATRICE ...

    SBIR Phase II 1987 Department of Health and Human Services
  10. ANTI-IDIOTYPIC MONOCLONAL ANTIBODY (AIMA) THERAPY HAS CURATIVE POTENTIAL FOR LOW-GRADE B-CELL LYMPHOMAS THROUGH IMMUNOLOGIC DOWN REGULATION OF THE MALIGNANT IDIOTYPIC CLONE AS WELL AS ANTIBODY-DEPENDENT CELL MEDIATED CYTOTOXICITY.

    SBC: Biomedical Research Laboratori            Topic: N/A

    ANTI-IDIOTYPIC MONOCLONAL ANTIBODY (AIMA) THERAPY HAS CURATIVE POTENTIAL FOR LOW-GRADE B-CELL LYMPHOMAS THROUGH IMMUNOLOGIC DOWN REGULATION OF THE MALIGNANT IDIOTYPIC CLONE AS WELL AS ANTIBODY-DEPENDENT CELL MEDIATED CYTOTOXICITY. PRODUCTION OF AIMA IS PATIENT-SPECIFIC AND LABOR INTENSIVE REQUIRING A MEDIAN OF 912 MONTHS UTILIZING THE CLASSICAL MURINE MYELOMA $ HUMAN B-CELL HYBRIDOMA APPROACH. THE ...

    SBIR Phase I 1985 Department of Health and Human Services
US Flag An Official Website of the United States Government